Skip to content
AusGrant
Federal Forecasted GRANTS-GOV-363557

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

National Institutes of Health (NIH) · Competitive grant · Science & Technology

At a glance

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is a federal competitive grant from National Institutes of Health for the science & technology sector. Eligible applicants: Public housing authorities/Indian housing authorities; State governments; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit. Applications are accepted on a rolling basis. Apply via the official listing at www.grants.gov.

Amount
See listing
Deadline
Rolling
Type
Competitive
Status
Forecasted

About this program

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to: Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and Enable a precision medicine approach to AD drug development. The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Who can apply

Public housing authorities/Indian housing authorities; State governments; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Public and State controlled institutions of higher education; City or township governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Native American tribal organizations (other than Federally recognized tribal governments); Native American tribal governments (Federally recognized); Private institutions of higher education; County governments. Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

How to apply

Apply through Grants.gov using funding opportunity number RFA-AG-28-009. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.

Apply at official source